Diamond Ranch Foods (PLPL) 0.0340 $PLPL
Plandai Biotechnology Files 10-K for 2015, Discusses Future Filings, 2016 Operating Results, and Company Future
Marketwired - Wed Jul 06, 6:00AM CDT
LONDON, UNITED KINGDOM--(Marketwired - Jul 6, 2016) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"
, producer of the highly bioavailable Phytofare® catechin complex, today discussed the recent filing of the Company's financial statements for the year ended June 30, 2015, filed last week on Form 10-K, and announced that the quarterly reports for the first, second and third quarters of the current year being prepared for review. The Company anticipates that all delinquent filings will be made in the coming weeks with a goal of being fully reporting and relisted on the OTCQB by the end of August 2016.
Plandai Biotechnology to Host Investor Update Conference Call on Friday June 3, 2016 11a.m. ET
Marketwired - Wed Jun 01, 12:29PM CDT
LONDON, UNITED KINGDOM--(Marketwired - Jun 1, 2016) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company", producer of the highly bioavailable Phytofare® catechin complex, today announced it will be hosting an investor update conference call for Friday, June 3, at 11a.m. Eastern Time. The call will feature Board of Directors member and vice president of sales and marketing, Mr. Callum Cottrell-Duffield. The conference call dial-in information is:
Plandai Biotechnology, Inc. Announces New Process That Could Pave the Way to Using Phytofare for Domestic Animals Including Livestock and Pets
Marketwire Canada - Tue May 24, 6:01AM CDT
Revised Trial Expected to Commence June 2016
Plandai Biotechnology, Inc. Announces Vitamin Express to Release New Product Containing Phytofare(R)
Marketwired - Tue May 10, 6:00AM CDT
LONDON, UNITED KINGDOM--(Marketwired - May 10, 2016) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company", producer of the highly bioavailable Phytofare® catechin complex, today announced VitaminExpress, a highly successful health supplement company based in the European Union, is set to release a new product this month, with Phytofare® Catechin Complex as the main ingredient, which will be incorporated into their current product line. Vitamin Express has shipped an astounding 5 million products over the previous 20 years, with customers throughout Western and Eastern Europe.
Plandai Biotechnology, Inc. Announces Record Sales Volume for April
Marketwired - Fri Apr 29, 6:00AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company", producer of the highly bioavailable Phytofare(R) catechin complex, today announced that April 2016 saw the company sell and ship 425 kilograms of product, representing approximately $60,000 in revenues. In addition, since January, Plandai announced that customers have released to market a total of ten new branded consumer products that contain Phytofare(R), which are being sold in Australia, Western Europe and Africa. Products containing Phytofare(R) should be on shelves in United States as early as May.
Plandai Biotechnology, Inc. Announces First Shipment of Product to USA Customers
Marketwired - Thu Apr 07, 6:00AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company", producer of the highly bioavailable Phytofare(R) catechin complex, today announced that it has commenced shipping product to customers in the United States, a first for the London-based company that has thus far primarily sold in Africa and Western Europe. The first order, to be delivered by the end of April, will be formulated into nutriceutical products to be sold in the US and elsewhere by Ultimate Sports Nutrition (www.usn.co.za).
Plandai Biotechnology, Inc. Announces New Distributor to Boost Worldwide Sales
Marketwired - Wed Mar 30, 6:00AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company", producer of biopharmaceutical products including the highly bioavailable Phytofare(R) catechin complex, today announced that it has signed a distribution agreement with California-based AIDP Inc. that will enable them to offer Phytofare(R) to their established customer base throughout the world. This agreement will create a way for the company to sell to a wider clientele, including the United States, whereas existing distribution has focused primarily on Europe and Africa.
Plandai Biotechnology, Inc. Announces 2nd Quarter Sales and Gives Forecast for Q3
Marketwired - Mon Mar 28, 3:30PM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company", producer of the highly bioavailable Phytofare(R) catechin complex, today announced that it has sold and shipped over half a ton (640kg) of Phytofare(R) Catechin Complex to customers on four continents during the quarter ending March 31, 2016, its first full quarter of sales. The bulk of these sales were to customers in South Africa and Europe, with initial orders also being filled for Australia and India.
Plandai Biotechnology, Inc. Receives Initial Order From Coyne Healthcare
Marketwired - Tue Mar 15, 8:00AM CDT
Plandai Biotechnology, Inc. (OTC PINK: PLPL) ("Plandai" or "the Company", biopharmaceutical producer of the highly bioavailable Phytofare(R) catechin complex, today announced that it has received an initial order for 500,000 capsules of the Company's Pheroid(R) entrapped Phytofare(R) catechin complex -- trade named "ph^2(TM)" from Coyne Healthcare, leading developer of high-quality nutraceutical and food supplements based in South Africa. Plandai previously announced that it had entered into a license and supply agreement with Coyne Healthcare to develop a new biopharmaceutical product using ph2TM under which Plandai will prepare the capsules for Coyne who will then bottle, package and sell the product. Coyne Healthcare indicated that this initial order will be sold exclusively in South Africa but their intention is to expand the product internationally in the future.
Plandai Biotechnology, Inc. Announces Relocation of Sales Office to London, England and Other Corporate Changes
Marketwired - Thu Mar 03, 8:01AM CST
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company", a producer of the highly bioavailable Phytofare(R) catechin complex, today announced that it has relocated its sales offices to London, England, to better accommodate the growing demand for product and maintain a strategic position that accommodates operations in Europe, North America and South Africa. Previously, all sales were handled from the Company's offices in South Africa.
Plandai Biotechnology reports sale of Phytofare in three continents
M2 - Tue Jan 26, 3:06AM CST
Phyto-available extract company Plandai Biotechnology (OTCQB
LPL) reported on Monday that Phytofare is being marketed and sold in Africa, Europe and Australia.
Plandai Biotechnology, Inc. Announces Phytofare Sales on Three Continents
Marketwired - Mon Jan 25, 8:01AM CST
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company", producer of the highly bioavailable Phytofare(R) catechin complex, today announced that the Company is actively selling Phytofare(R) in Africa, Europe and Australia, where various customers use Phytofare(R) as the active ingredient in their formulated products. Sales of Phytofare(R) to United States customers are considered imminent, with sales to China anticipated later in the year.
Plandai Biotechnology, Inc. Announces Phytofare(R) Used as Key Ingredient in New Fat Burner Product
Marketwired - Wed Jan 13, 10:08AM CST
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company", producer of the highly bioavailable Phytofare(R) catechin complex, today announced that TNT Supplements recently launched their new product, TNT Fat Burner, in the United Kingdom. TNT contains a unique blend of ingredients that have never before been used in tandem, one of which is Plandai's Phytofare(R) catechin complex. Phytofare(R) is a highly bioavailable green tea-based extract that is unique in having clinical data demonstrating ten times greater bioavailability over generic green tea extracts. Furthermore, Phytofare(R) consists of all eight catechins found in green tea, not just ECGC which is found in most weight loss products.
Plandai Biotechnology, Inc. Gives Annual Report of Progress and Provides Projections for 2016
Marketwired - Mon Dec 28, 8:00AM CST
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company", a producer of highly bioavailable Phytofare(R) Catechin Complex, today reviewed the results and current standings for 2015 and discussed plans for the future as they look to 2016.
Plandai Biotechnology, Inc. Reaches Agreement With Deltamune to Study Commercial Potential of Phytofare in Livestock
Marketwired - Wed Nov 18, 8:01AM CST
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company", producer of the highly bioavailable Phytofare(R) catechin complex, today announced that its wholly-owned subsidiary, Red Gold (Pty) Ltd., has reached an agreement with Deltamune (Pty) Ltd., a South African-based veterinary research and testing company that also develops and manufactures vaccines for treating Avian Influenza, Infectious Coryza, Egg Drop syndrome and Newcastle disease. Under the terms of the agreement, Deltamune will undertake clinical trials using Plandai's Phytofare(R) Catechin Complex and Citrus Complex to determine the efficacy of the combined all-natural products in helping prevent diseases in poultry. Should the trials prove successful, the parties will move towards executing a production license and distribution agreement.
Plandai Biotechnology signs Phytofare distribution agreement with Bal Pharma Ltd for India
M2 - Wed Oct 28, 5:14AM CDT
Plandai Biotechnology (OTCQBLPL) reported on Tuesday the launch of an exclusive Phytofare distribution Agreement with Bal Pharma, an India-based manufacturer and exporter of pharmaceutical finished formulation/bulk drugs and distributor of nutraceuticals ingredients.
Plandai Biotechnology, Inc. Announces Distribution Agreement With Bal Pharma Ltd Covering India
Marketwired - Tue Oct 27, 8:33AM CDT
Plandai Biotechnology, Inc. ("Plandai" or "the Company" (OTCQB: PLPL), producer of the highly bioavailable Phytofare(R), today announced that it has executed an Exclusive Distribution Agreement with Bal Pharma Ltd., an India-based manufacturer and exporter of pharmaceutical finished formulation/bulk drugs and distributor of nutraceuticals ingredients (www.balpharma.com). Under the terms of the agreement, Bal Pharma will use the Company's Phytofare(R) in their finished formulation products while also distributing Phytofare(R) as an active ingredient throughout India. The two-year renewable agreement gives Bal Pharma exclusivity for their territory and fixed pricing based on volume in exchange for defined annual off take.
Plandai Biotechnology Files 10-K for 2015, Discusses Future Filings, 2016 Operating Results, and Company Future
Marketwired - Wed Jul 06, 6:00AM CDT
LONDON, UNITED KINGDOM--(Marketwired - Jul 6, 2016) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"
, producer of the highly bioavailable Phytofare® catechin complex, today discussed the recent filing of the Company's financial statements for the year ended June 30, 2015, filed last week on Form 10-K, and announced that the quarterly reports for the first, second and third quarters of the current year being prepared for review. The Company anticipates that all delinquent filings will be made in the coming weeks with a goal of being fully reporting and relisted on the OTCQB by the end of August 2016. Plandai Biotechnology to Host Investor Update Conference Call on Friday June 3, 2016 11a.m. ET
Marketwired - Wed Jun 01, 12:29PM CDT
LONDON, UNITED KINGDOM--(Marketwired - Jun 1, 2016) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"
, producer of the highly bioavailable Phytofare® catechin complex, today announced it will be hosting an investor update conference call for Friday, June 3, at 11a.m. Eastern Time. The call will feature Board of Directors member and vice president of sales and marketing, Mr. Callum Cottrell-Duffield. The conference call dial-in information is: Plandai Biotechnology, Inc. Announces New Process That Could Pave the Way to Using Phytofare for Domestic Animals Including Livestock and Pets
Marketwire Canada - Tue May 24, 6:01AM CDT
Revised Trial Expected to Commence June 2016
Plandai Biotechnology, Inc. Announces Vitamin Express to Release New Product Containing Phytofare(R)
Marketwired - Tue May 10, 6:00AM CDT
LONDON, UNITED KINGDOM--(Marketwired - May 10, 2016) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"
, producer of the highly bioavailable Phytofare® catechin complex, today announced VitaminExpress, a highly successful health supplement company based in the European Union, is set to release a new product this month, with Phytofare® Catechin Complex as the main ingredient, which will be incorporated into their current product line. Vitamin Express has shipped an astounding 5 million products over the previous 20 years, with customers throughout Western and Eastern Europe. Plandai Biotechnology, Inc. Announces Record Sales Volume for April
Marketwired - Fri Apr 29, 6:00AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company"
, producer of the highly bioavailable Phytofare(R) catechin complex, today announced that April 2016 saw the company sell and ship 425 kilograms of product, representing approximately $60,000 in revenues. In addition, since January, Plandai announced that customers have released to market a total of ten new branded consumer products that contain Phytofare(R), which are being sold in Australia, Western Europe and Africa. Products containing Phytofare(R) should be on shelves in United States as early as May. Plandai Biotechnology, Inc. Announces First Shipment of Product to USA Customers
Marketwired - Thu Apr 07, 6:00AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company"
, producer of the highly bioavailable Phytofare(R) catechin complex, today announced that it has commenced shipping product to customers in the United States, a first for the London-based company that has thus far primarily sold in Africa and Western Europe. The first order, to be delivered by the end of April, will be formulated into nutriceutical products to be sold in the US and elsewhere by Ultimate Sports Nutrition (www.usn.co.za). Plandai Biotechnology, Inc. Announces New Distributor to Boost Worldwide Sales
Marketwired - Wed Mar 30, 6:00AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company"
, producer of biopharmaceutical products including the highly bioavailable Phytofare(R) catechin complex, today announced that it has signed a distribution agreement with California-based AIDP Inc. that will enable them to offer Phytofare(R) to their established customer base throughout the world. This agreement will create a way for the company to sell to a wider clientele, including the United States, whereas existing distribution has focused primarily on Europe and Africa. Plandai Biotechnology, Inc. Announces 2nd Quarter Sales and Gives Forecast for Q3
Marketwired - Mon Mar 28, 3:30PM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company"
, producer of the highly bioavailable Phytofare(R) catechin complex, today announced that it has sold and shipped over half a ton (640kg) of Phytofare(R) Catechin Complex to customers on four continents during the quarter ending March 31, 2016, its first full quarter of sales. The bulk of these sales were to customers in South Africa and Europe, with initial orders also being filled for Australia and India. Plandai Biotechnology, Inc. Receives Initial Order From Coyne Healthcare
Marketwired - Tue Mar 15, 8:00AM CDT
Plandai Biotechnology, Inc. (OTC PINK: PLPL) ("Plandai" or "the Company"
, biopharmaceutical producer of the highly bioavailable Phytofare(R) catechin complex, today announced that it has received an initial order for 500,000 capsules of the Company's Pheroid(R) entrapped Phytofare(R) catechin complex -- trade named "ph^2(TM)" from Coyne Healthcare, leading developer of high-quality nutraceutical and food supplements based in South Africa. Plandai previously announced that it had entered into a license and supply agreement with Coyne Healthcare to develop a new biopharmaceutical product using ph2TM under which Plandai will prepare the capsules for Coyne who will then bottle, package and sell the product. Coyne Healthcare indicated that this initial order will be sold exclusively in South Africa but their intention is to expand the product internationally in the future. Plandai Biotechnology, Inc. Announces Relocation of Sales Office to London, England and Other Corporate Changes
Marketwired - Thu Mar 03, 8:01AM CST
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company"
, a producer of the highly bioavailable Phytofare(R) catechin complex, today announced that it has relocated its sales offices to London, England, to better accommodate the growing demand for product and maintain a strategic position that accommodates operations in Europe, North America and South Africa. Previously, all sales were handled from the Company's offices in South Africa. Plandai Biotechnology reports sale of Phytofare in three continents
M2 - Tue Jan 26, 3:06AM CST
Phyto-available extract company Plandai Biotechnology (OTCQB
LPL) reported on Monday that Phytofare is being marketed and sold in Africa, Europe and Australia. Plandai Biotechnology, Inc. Announces Phytofare Sales on Three Continents
Marketwired - Mon Jan 25, 8:01AM CST
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company"
, producer of the highly bioavailable Phytofare(R) catechin complex, today announced that the Company is actively selling Phytofare(R) in Africa, Europe and Australia, where various customers use Phytofare(R) as the active ingredient in their formulated products. Sales of Phytofare(R) to United States customers are considered imminent, with sales to China anticipated later in the year. Plandai Biotechnology, Inc. Announces Phytofare(R) Used as Key Ingredient in New Fat Burner Product
Marketwired - Wed Jan 13, 10:08AM CST
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company"
, producer of the highly bioavailable Phytofare(R) catechin complex, today announced that TNT Supplements recently launched their new product, TNT Fat Burner, in the United Kingdom. TNT contains a unique blend of ingredients that have never before been used in tandem, one of which is Plandai's Phytofare(R) catechin complex. Phytofare(R) is a highly bioavailable green tea-based extract that is unique in having clinical data demonstrating ten times greater bioavailability over generic green tea extracts. Furthermore, Phytofare(R) consists of all eight catechins found in green tea, not just ECGC which is found in most weight loss products. Plandai Biotechnology, Inc. Gives Annual Report of Progress and Provides Projections for 2016
Marketwired - Mon Dec 28, 8:00AM CST
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company"
, a producer of highly bioavailable Phytofare(R) Catechin Complex, today reviewed the results and current standings for 2015 and discussed plans for the future as they look to 2016. Plandai Biotechnology, Inc. Reaches Agreement With Deltamune to Study Commercial Potential of Phytofare in Livestock
Marketwired - Wed Nov 18, 8:01AM CST
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company"
, producer of the highly bioavailable Phytofare(R) catechin complex, today announced that its wholly-owned subsidiary, Red Gold (Pty) Ltd., has reached an agreement with Deltamune (Pty) Ltd., a South African-based veterinary research and testing company that also develops and manufactures vaccines for treating Avian Influenza, Infectious Coryza, Egg Drop syndrome and Newcastle disease. Under the terms of the agreement, Deltamune will undertake clinical trials using Plandai's Phytofare(R) Catechin Complex and Citrus Complex to determine the efficacy of the combined all-natural products in helping prevent diseases in poultry. Should the trials prove successful, the parties will move towards executing a production license and distribution agreement. Plandai Biotechnology signs Phytofare distribution agreement with Bal Pharma Ltd for India
M2 - Wed Oct 28, 5:14AM CDT
Plandai Biotechnology (OTCQB
LPL) reported on Tuesday the launch of an exclusive Phytofare distribution Agreement with Bal Pharma, an India-based manufacturer and exporter of pharmaceutical finished formulation/bulk drugs and distributor of nutraceuticals ingredients. Plandai Biotechnology, Inc. Announces Distribution Agreement With Bal Pharma Ltd Covering India
Marketwired - Tue Oct 27, 8:33AM CDT
Plandai Biotechnology, Inc. ("Plandai" or "the Company"
(OTCQB: PLPL), producer of the highly bioavailable Phytofare(R), today announced that it has executed an Exclusive Distribution Agreement with Bal Pharma Ltd., an India-based manufacturer and exporter of pharmaceutical finished formulation/bulk drugs and distributor of nutraceuticals ingredients (www.balpharma.com). Under the terms of the agreement, Bal Pharma will use the Company's Phytofare(R) in their finished formulation products while also distributing Phytofare(R) as an active ingredient throughout India. The two-year renewable agreement gives Bal Pharma exclusivity for their territory and fixed pricing based on volume in exchange for defined annual off take. 
